Skip to main content
. Author manuscript; available in PMC: 2012 Mar 2.
Published in final edited form as: Future Med Chem. 2011 May;3(7):821–833. doi: 10.4155/fmc.11.47

Table 2.

Phenolic class activators.

Name (proposed mode of action) Chemical structure Biochemical assay
Cell-based assay
Activity Substrate PP2A Selectivities Activity Cell type
Tetralone (direct in the presence of ceramide) graphic file with name nihms311211t5.jpg 520% (20 μM; in the presence of C2-cer) Phosphorylated myelin basic protein Purified heterotrimer from Jurkat cells Yes vs PP1 Not reported Not reported
Quinolone (direct in the presence of ceramide) graphic file with name nihms311211t6.jpg 400% (20 μM; in the presence of C2-cer) Phosphorylated myelin basic protein Purified heterotrimer from Jurkat cells Yes vs PP1 Not reported Not reported
(-)-epigallocatechin gallate (PP2A methylesterase) graphic file with name nihms311211t7.jpg 129% (100 μM) Antogonistic to OA IC50~80 μM ABC No effect (p-histoneH1) AC Not reported Not reported Not reported
Dihydroxyphenylethano (direct) graphic file with name nihms311211t8.jpg 500% (400 μM) Phosphopeptide Recombinant C Yes vs PP1 780% (400 μM) HT-29 (synthetic phosphopeptide)
Methyl-3,5-diiodo-4-(4’-methoxyphenoxy) benzoate (direct) graphic file with name nihms311211t9.jpg 250% (10 μM) [32P]-histone H1 Purified red cell PP2A Substrate specific, but activates ALP 300% (10 μM) Eras 20 ([32P]-histone H1)
β-tocopherol (direct, synergistic with ceramide, PME) graphic file with name nihms311211t10.jpg 190% (50 μM) Phosphorylase a Purified red cell PP2A Yes vs PP1 500% (50 μM) A7r5 ([32P]-PKC)

PP: Phosphoprotein phosphatase.

HHS Vulnerability Disclosure